Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | CD274 neg MSH6 W628* |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
CD274 neg MSH6 W628* | glioblastoma | predicted - sensitive | Nivolumab | Case Reports/Case Series | Actionable | In a clinical case study, Opdivo (nivolumab) treatment resulted in a 60% reduction of tumor size and durable clinical response that was still ongoing after 10 months in a pediatric patient with refractory glioblastoma that was CD274 (PD-L1) negative, the patient was also diagnosed with constitutional mismatch repair-deficiency (CMMRD) syndrome due to biallelic MSH6 W628* mutation (PMID: 30104292). | 30104292 |